<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Radiofrequency ablation (RFA) is an accepted treatment for the eradication of dysplastic <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (<z:chebi fb="7" ids="28534">DBE</z:chebi>) and residual <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> after endoscopic resection of intramucosal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Circumferential balloon-based and focal catheter-based RFA devices are currently used (the Halo360 and Halo90) </plain></SENT>
<SENT sid="2" pm="."><plain>However, a new smaller focal ablation device (the Halo60) has been developed, which may be of benefit in patients with short tongues of Barrett's <z:hpo ids='HP_0002664'>neoplasia</z:hpo>, small residual islands, difficult <z:mp ids='MP_0000002'>anatomy</z:mp>, or strictures </plain></SENT>
<SENT sid="3" pm="."><plain>We report the first use of this device in 17 patients with either <z:chebi fb="7" ids="28534">DBE</z:chebi> or residual <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> after endoscopic resection of intramucosal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>